China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed for innovative R&D. The Chinese government set the target in its latest five-year plan for the pharma industry. From 2026 to 2030, the government wants to achieve a leap in the competitiveness and international influence of the industry, Xinhua reported. The state news agency was covering the five-year, Chinese-language plan that the National Medical Products Administration and eight other agencies published on Friday. Government policy supports China’s first-in-class drug target, which covers active clinical programs and approved products. Under the five-year plan, officials will support drugmakers’ pursuits of new targets, mechanisms and modalities. Major infectious and chronic diseases, plus rare and pediatric conditions, are focus areas for the government.

Full report : China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status in biotechnology.